Preparations for the start of production, technology transfer and testing have already begun. Novartis intends to manufacture the mRNA and the pre-formulated active substances for up to 50 million doses by the end of 2021 and for up to 200 million doses in 2022. The beginning of deliveries will likely take place as of the summer of 2021. Production will occur in an innovative, high-tech manufacturing plant which is already under construction and which will be adapted to the needs of vaccine production for CureVac.
CureVac is a global biopharmaceutical company in the field of mRNA technology with more than 20 years of experience in the development and optimisation of this versatile molecule for medical purposes. The company is headquartered in Tübingen, Germany, and employs a workforce of more than 600 employees at its sites in Tübingen, Frankfurt and Boston, USA.
Kundl is a central development and production site of the Novartis Group and headquarters of Sandoz GmbH with a focus on generic drug manufacturing. The plant in Kundl specialises in biotechnologically produced drugs, from research and development to production. The emphasis is on the production of active pharmaceutical ingredients for antibiotics and antibiotic finished dosage forms. The factory in Kundl was already established in the year 1946.
Continue reading and learn more about the life sciences sector in Austria!